HRMY · Harmony Biosciences Holdings, Inc.

$35.77 -0.24 (-0.67%) At close · Jul 28

Market Cap

$2.07B

57.89M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Dayno	CEO	$715,000	$300,000	$1,288,980	$4,189,508	$637,000	$14,683	$7,145,170
Kumar Budur	Chief Medical Officer	$555,147	—	$2,538,788	$2,420,116	$207,018	$11,636	$5,732,705
Sandip Kapadia	CFO	$507,606	$250,000	$468,023	$1,538,052	$291,873	$14,848	$3,070,401
Jeffrey Dierks	Chief Commercial Officer	$508,702	$250,000	$329,918	$1,087,511	$279,908	$14,871	$2,470,910
Andrew Serafin	Chief Strategy Officer	$420,294	$125,000	$306,900	$989,117	$231,262	$14,848	$2,087,422

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jeffrey Dierks	Chief Commercial Officer	$486,796	$50,000	$4,767,000	—	$279,908	$14,045	$5,597,749
Sandip Kapadia	CFO	$507,606	—	$4,767,000	—	$291,873	$14,045	$5,580,524
Jeffrey Dayno	CEO	$612,500	$200,000	—	$3,186,875	$437,000	$13,919	$4,450,294
Kumar Budur	Chief Medical Officer	$440,251	$100,000	—	—	$207,018	$13,545	$760,813
Andrew Serafin	Chief Strategy Officer	$402,195	—	—	—	$231,262	$13,968	$647,425
John C. Jacobs	CEO	$29,567	—	—	—	—	$7,067	$36,634

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sandip Kapadia	CFO	$476,625	$175,000	—	—	$297,891	$13,086	$962,602
Jeffrey Dayno	CEO	$458,993	—	—	—	$286,870	$16,289	$762,152
Jeffrey Dierks	Chief Commercial Officer	$412,072	—	—	—	$236,941	$13,086	$662,099
Andrew Serafin	Chief Strategy Officer	$375,673	—	—	—	$216,012	$13,737	$605,422
John C. Jacobs	CEO	$500,897	—	—	—	—	$13,856	$514,752

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Sandip Kapadia	CFO	$354,155	$175,000	$1,741,800	$3,765,100	$185,267	$2,610	$6,223,933
Jeffrey Dierks	Chief Commercial Officer	$308,703	$172,873	—	$2,218,128	—	$878	$2,700,383
John C. Jacobs	CEO	$488,680	—	—	—	$384,835	$12,039	$885,554
Jeffrey Dayno	Chief Medical Officer	$445,624	—	—	—	$245,093	$12,027	$702,744
Susan Drexler	CFO	$83,103	—	—	—	—	$285,446	$368,549
Andrew Serafin	Chief Strategy Officer	—	—	—	—	—	—	—

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John C. Jacobs	CEO	$473,068	$460,035	—	$2,296,436	—	$835	$3,230,734
Jeffrey Dayno	Chief Medical Officer	$431,388	$301,972	—	$1,968,249	—	$885	$2,702,943
Jeffrey Dierks	Chief Commercial Officer	$308,703	$172,873	—	$2,218,128	—	$878	$2,700,383
Andrew Serafin	Chief Strategy Officer	—	—	—	—	—	—	—
Sandip Kapadia	CFO	—	—	—	—	—	—	—
Susan Drexler	CFO	—	—	—	—	—	—	—

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
John C. Jacobs	CEO	$454,000	$391,575	—	—	—	$88	$845,663
Jeffrey Dayno	Chief Medical Officer	$414,000	$238,050	—	$20,000	—	$148	$672,175
Andrew Serafin	Chief Strategy Officer	—	—	—	—	—	—	—
Jeffrey Dierks	Chief Commercial Officer	—	—	—	—	—	—	—
Sandip Kapadia	CFO	—	—	—	—	—	—	—
Susan Drexler	CFO	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Stephen Mollichella	Interim Principal Financial Officer	Appointed	2026-07-16	2026-07-16
Glenn Reicin	Chief Financial Officer	Appointed	2026-04-14	2026-04-14
Peter Anastasiou	Class III member of the board of directors	Resigned	2026-04-02	2026-04-02
Peter Anastasiou	Senior Executive Vice President and Chief Operating Officer	Appointed	2026-04-02	2026-04-02

Key facts CIK 1802665 CUSIP 413197104 13F (30d) 56 filings 56 filers Visit website Investor relations